Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Oct 30 - Nov 4
10.1007/s10295-019-02145-x J
This expert oversight is what makes the treatment both safe and effective, giving you peace of mind and a clear path toward your wellness goals
A Phase I/II trial published in the Journal of Clinical Endocrinology & Metabolism (2006) studied CJC-1295 with DAC in healthy adults aged 21-61: Single doses of 30, 60, or 125 g/kg produced dose-dependent increases in GH and IGF-1 Mean GH levels increased 2-10 fold for up to 6 days after a single injection IGF-1 levels increased 1.5-3 fold and remained elevated for 9-11 days After 2-3 weekly doses, steady-state IGF-1 elevation was achieved The most common adverse events were injection site reactions, headache, and diarrhea No serious adverse events were reported in the study timeframe Important Context: ConjuChem's clinical development program for CJC-1295 with DAC was discontinued after a subject death in a subsequent trial
GLP-1 Agonists Market size was valued at US$ 37,113.2 billion in 2025 and is expected to reach US$ 118,926.1 billion by 2032, growing at a significant CAGR of 18.1% from 2026-2032
Magnolol helps promote the skins natural production of healthy adipose tissue to improve radiance, enhance volume and restore a more youthful-looking glow
